- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05213702
A RCT to Evaluate the Efficacy and Safety of Automated Needle Targeting (ANT-X) System Compared to Traditional Free Hand Puncture for Renal Access in Percutaneous Nephrolithotomy (PCNL)
A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Automated Needle Targeting (ANT-X) System Compared to Traditional Free Hand Puncture for Renal Access in Percutaneous Nephrolithotomy (PCNL) Performed by Urologists in Training.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single centre, participant randomized, open label study to evaluate the efficacy and safety of automated needle targeting (ANT-X) system compared to traditional free hand puncture for achieving renal access in Percutaneous lithotomy (PCNL) performed by urologists in training.
Prior to performing kidney puncture on patients, all participating surgeons will undergo a simulation using Medical Simulation 12 balls phantom device with and without use of the ANT-X. Four urologic trainees (with similar little previous PCNL experience) will be recruited for the simulation. Two end points will be assessed: Number of attempts to achieve desired renal puncture and total fluoroscopy time.
This simulation via 12 balls phantom device will involve fluoroscopic screening of calyx and successful puncture by urologic trainees under consultant supervision. Trainees will have 30 attempts of free hand puncture and 30 attempts using the ANT-X. The trainee will only move on to patient's renal puncture once they are able to achieve more than 80% of satisfactory renal puncture on simulator.
For human renal puncture, we will aim for 60 cases of PCNL, 30 to be done using ANT-X puncture and 30 using traditional free hand puncture performed by 4 urologic trainees (15 cases per urologic trainee).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: WS Yeoh, MD
- Phone Number: 2981 +60379494499
- Email: yeoh_uro@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects willing to sign informed consent form before initiation of any study specific procedures.
- Subjects diagnosed with kidney stones and planned for prone PCNL.
- Male/ non- pregnant female subjects between 18-75 years (both inclusive) of age at the time of informed consent.
- Subjects with renal stones of ≥1 cm or not managed by other stone treatments (e.g. shock wave lithotripsy, ureteroscopy).
- Serum creatinine of < 1.2 mg/dl.
Exclusion Criteria:
- Subjects with bleeding disorders.
- Recent infection of the kidney or urinary tract which leads to pus accumulation in the kidney, i.e., Pyonephrosis.
- Subjects not able to have prone positions for surgical procedure due to comorbid conditions.
- Renal stones < 1 cm and can managed by another technique.
- Patients with moderate to severe renal failure.
- Patients with congenital urinary tract anomalies.
- Patients on anticoagulation or antiplatelet therapy.
- Evidence or history of any other disease that in the opinion of the investigator would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
- Legal incapacity or other circumstances that render the subject unable to understand the nature, scope and possible consequences of the study.
- Clinically significant abnormal findings or condition (other than kidney stone), which might, in the opinion of the Investigator, interfere with study evaluations or pose a risk to subject safety during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Traditional free hand puncture for renal calyx access
For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
|
ANT-X device is a software-controlled automated electromechanical arm.
It is developed to provide needle guidance for surgeon in MIS.
This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient.
ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement.
Parallel structures excel in their great stiffness and high positioning accuracy.
Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material.
PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength.
The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology).
The fluoroscopy technology is used to provide image guidance for the needle
|
ACTIVE_COMPARATOR: RObotic ANT-X device puncture for renal calyx access
For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
|
ANT-X device is a software-controlled automated electromechanical arm.
It is developed to provide needle guidance for surgeon in MIS.
This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient.
ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement.
Parallel structures excel in their great stiffness and high positioning accuracy.
Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material.
PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength.
The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology).
The fluoroscopy technology is used to provide image guidance for the needle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of attempts required to obtain access
Time Frame: Day 0 surgery
|
An access attempt is defined as each separate passage of the needle into the kidney.
Number of attempts by Investigator/surgeon will be recorded.
|
Day 0 surgery
|
Time for the access
Time Frame: Day 0 surgery
|
Time to successful access into the collecting system will be calculated in minutes starting from the placement of the needle on the skin surface to the identification of urine efflux from the end of the needle or reach of target.
Start time of needle placement and time of urine efflux from the end of the needle or reach of target will be recorded in subject CRF in hh:mm:ss format.
|
Day 0 surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiation exposure to patient and surgeon
Time Frame: Day 0 surgery
|
Day 0 surgery
|
|
Assessment of AEs
Time Frame: Admission day till discharge within 7 days
|
Advere events associated with the procedure
|
Admission day till discharge within 7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: WS Yeoh, MD, UMMC
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NDR-CT0023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Stone
-
Washington University School of MedicineRecruiting
-
Société Internationale d'UrologieCompletedStone Ureter | Stone, Kidney | Stone;RenalUnited States, China, Korea, Republic of, Malaysia, Saudi Arabia, Greece, India, Indonesia, Iran, Islamic Republic of, Iraq, Kenya, Romania, South Africa, Taiwan, Turkey
-
Wake Forest University Health SciencesCogenix Medical CorporationWithdrawnKidney Stone | Renal Stone | Ureter StoneUnited States
-
Advance Shockwave Technology GmbHUnknownKidney StonesUnited States
-
Mansoura UniversityCompletedUrologic Diseases | Stone, Kidney | Stone, Urinary | ESWL | Radiolucent Calculus of Urinary Tract | DissolutionEgypt
-
University of British ColumbiaActive, not recruiting
-
Mansoura UniversityUnknownUrologic Diseases | Stones, Kidney | Stone, Urinary | Shock Wave LithotripsyEgypt
-
Selcuk UniversityThe Scientific and Technological Research Council of TurkeySuspendedKidney StonesTurkey
-
Mansoura UniversityCompleted
-
Alnylam PharmaceuticalsTerminatedRecurrent Calcium Oxalate Kidney Stone Disease | Elevated Urinary Oxalate LevelsUnited States, Italy, Spain, Belgium, Switzerland, United Kingdom